Vienna, Austria – 17 July 2025 — Resonate Bio, a new biotech innovator and spin-off from the University of Vienna, is proud to announce its official launch and exclusive licensing of breakthrough software powering its AI-NMR drug discovery platform.
Combining artificial intelligence and nuclear magnetic resonance (NMR) spectroscopy, Resonate Bio’s technology radically accelerates drug development by decoding complex molecular interactions with precision and speed, especially for dynamic proteins. The proprietary AI-NMR drug discovery platform was developed through years of research within the Christian Doppler Laboratory between the University of Vienna and Boehringer Ingelheim.
“This platform is more than an algorithm – it’s a new lens through which we can see “movies” of protein-ligand complexes in high resolution and high-throughput,” said Dr. Darryl McConnell, Co-Founder and Chief Executive Officer of Resonate Bio. “The University of Vienna gave us a foundation, and now we’re ready to amplify its impact to drug discovery.”
Resonate Bio’s spin-out builds upon scientific foundations established at the University of Vienna, reflecting the potential for academic research at the University of Vienna to spark technological innovation. Through the software licensing, the company now advances its AI-NMR platform toward application – enabling Resonate Bio to unlock novel therapeutics where it wasn’t possible before.
“We believe that combining AI approaches with biophysical measurements is the missing approach in the AI revolution in Drug Discovery,” said Prof. Robert Konrat, Co-Founder and Chief Technology Officer of Resonate Bio.
With initial partnerships already underway, Resonate Bio aims to reshape early-stage drug discovery, especially for hard-to-target protein systems such as dynamic proteins.
About Resonate Bio – Resonate Bio is a Vienna-based biotech company pioneering the use of artificial intelligence and nuclear magnetic resonance (AI-NMR) to bring “movies” to structure-based drug design and in doing so drug “undruggable” dynamic proteins across therapeutic areas.
To learn more, visit https://www.resonate.bio or contact media@resonate.bio.